Please assess the completion status of the following clinical trial:

Trial Title: Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* PD diagnosed within the past 5 years~* Taking a monoamine oxidase (MAO) inhibitor~* Able to provide consent~* At least18 years old~EXCLUSION CRITERIA:~* Taking levodopa in any form~* Known allergy to NAC~* Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ)~* A condition that would increase risk from a lumbar puncture (e.g., symptomatic spinal stenosis or myoclonus)~* History of a post-spinal headache that required treatment with a blood patch~* On a prescribed anti-coagulant (e.g., Coumadin, Plavix)~* Pregnant or breast-feeding~* History of alcohol or drug abuse~* Any medical condition thatcould put subjects at increased risk. Potential participants are excluded who have evidence of bone marrow, liver, or kidney failure based on abnormal screening lab results.~* On a medication that could interfere with the scientific results. An example of an exclusionary drug is the catechol-O-methyltransferase inhibitor entacapone. Tricyclic anti-depressants are another type of exclusionary drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: EXPERIMENTAL): HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
- PD Patients (Type: EXPERIMENTAL): Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).